UM Slovakia has been tapped by Glenmark Pharmaceuticals to handle the relaunch of its popular pain medication, Ataralgin.

Although a household name in Slovakia and the Czech Republic, Ataralgin has recently seen its market share decline. In an attempt to regain its prominence, Glenmark looked to UM to generate a 2-part pitch aimed at regaining lost market share.

Our Slovakian team delivered on all fronts, presenting Glenmark with a comprehensive media market and competitive overview, a strategic television campaign and competitive cost analysis.

In the end, UM’s signature innovation and Curiosity proved to be the winning ticket.

The campaign is currently running through November.

Congrats to the Slovakian crew on yet another success!